Celltrion Healthcare Canada

Session on Friday, November 13 at 16:00

Since its inception in 2001, Celltrion Healthcare has grown into a global leader in biosimilars, operating in over 110 countries. The company aims to provide affordable, innovative treatments worldwide, recently expanding its reach to Canada. In 2021, Celltrion received Health Canada approval for Remsima™ SC, a subcutaneous treatment for rheumatoid arthritis, and Yuflyma®, a biosimilar to Humira® for various chronic inflammatory conditions. In 2023, Vegzelma™ was also approved for treating multiple cancers. Celltrion Healthcare continues to focus on expanding its portfolio and providing effective therapies to Canadian patients.

Friday, November 1316:00 – 16:3030 minOpen Pres.

Chronic Spontaneous Urticaria Management: Bridging Dermatology and Allergy Perspectives

Dr. Gordon Sussman

Dr. Charles Lynde

Learning objectives

Recognize the burden of chronic spontaneous urticaria (CSU) in Canadian practice and the role of the dermatologist in its management
Apply a guideline-based, step-care approach to CSU in alignment with international recommendations
Contextualize newer and emerging agents alongside omalizumab, weighing efficacy, onset, durability, and safety maturity.
Identify opportunities to optimize collaboration between dermatologists and allergists to improve CSU patient care

DermUpdateSee it in the program

Celltrion Healthcare Canada

Celltrion Healthcare Canada

Sessions at Dermatology Update — Fall 2026

Chronic Spontaneous Urticaria Management: Bridging Dermatology and Allergy Perspectives